Leading Advisory Firms Back Lynx1's Independent Nominees for Neuphoria Board Seats

Lynx1, a shareholder of Neuphoria Therapeutics, has received recommendations from leading proxy advisory firms Glass Lewis and Egan-Jones to vote for Lynx1's independent nominees. Glass Lewis recommends voting for Stephen Doberstein, Ph.D., while Egan-Jones recommends voting for both Doberstein and Kimberly Smith. Shareholders are urged to vote for Lynx1's nominees on the BLUE card to ensure meaningful boardroom change and restore credibility, discipline, and value for patients and stakeholders.